Search

- Jul 19
Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm
Al Collinson of TheracosBio discusses his plan to sell the SGLT2 inhibitor Brenzavvy for a deeply discounted price.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square